- Not Fee assured
- Awaiting verification
- Open Referral network
Offers
- Face-to-face consultations
- Home chemotherapy
About me
Dr Naveed Sarwar was appointed to Imperial College Healthcare NHS trust in 2014 to lead the Medical Oncology group, in the treatment of urological cancers having previously been a Consultant at Barts Health NHS trust since 2008. He is the deputy lead for the Charing Cross Trophoblast Screening and Treatment Centre. He is a member of the National Cancer Research Institute clinical studies group for testicular cancer and also a member of the National Cancer Research Institute clinical studies group for metastatic bladder cancer.
Dr Sarwar is very actively involved in clinical trial research leading a spectrum of clinical studies from phase II to randomized Phase III. He is the lead for urological medical oncology at Charing Cross Hospital, and the research lead for the treatment of urological cancers within NW Thames network. He has co-authored papers on urological cancers and Gestational Trophoblast Disease in peer-reviewed journals. He is a member of both the European and American Societies of Oncology and a keen participant in their annual meetings.
Areas of interest
Urological oncology; Kidney Cancer; Prostate Cancer; Bladder Cancer; Testicular Cancer; Ovarian Germ Cell Cancer; Molar Pregnancy; Gestational Trophoblastic Disease; Immunotherapy
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)
Charing Cross Hospital (5-50)
-
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
Charing Cross Hospital (5-50)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
Charing Cross Hospital (5-50)
-
X0001
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 0-7 days - (1-5)
Charing Cross Hospital (1-5)